We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie and Eli Lilly have hit fresh 52-week highs, outperforming the broader market amid tech volatility.
AbbVie's strong immunology drug sales and rising dividend reinforce its defensive appeal.
Eli Lilly's booming obesity drug sales and robust growth support its long-term upside potential.
With technology stocks retreating amid concerns about lofty AI valuations and massive infrastructure spending, investors may want to consider defensive healthcare stocks that are showing impressive relative strength.
Notably, AbbVie (ABBV - Free Report) ) and Eli Lilly (LLY - Free Report) ) stocks have hit fresh 52-week highs after posting strong Q3 results last week, highlighting investors' appetite for established healthcare companies with resilient demand, strong earnings potential, and attractive long-term growth prospects.
Both stocks are up more than 25% in 2026 and have outperformed the broader market with returns of more than 100% in the last three years.
Image Source: Zacks Investment Research
AbbVie's Strong Growth & Rising Dividend
Hitting a fresh 52-week high of $302 a share on Thursday, AbbVie’s ascent has been supported by strong demand for its blockbuster immunology treatments Skyrizi and Rinvoq.
AbbVie's Q3 revenue climbed 10% year over year to $17.4 billion, with adjusted earnings more than doubling to $3.82 per share. Management also raised its full-year adjusted EPS outlook to a range of $13.95-$13.99, which would reflect more than 39% growth.
Adding to its defensive appeal, AbbVie recently announced a 5.2% dividend increase for 2027 to a quarterly payout of $1.82 per share, reinforcing its commitment to shareholder returns with a dividend yield comfortably above 2%.
Image Source: Zacks Investment Research
Eli Lilly's Explosive Obesity Drug Growth
Eli Lilly has emerged as one of the medical sector's strongest growth stories, with LLY shares also hitting a 52-week peak in today’s trading session of $1,453 a share.
Demand for blockbuster diabetes and obesity treatments Mounjaro and Zepbound continues to fuel exceptional growth. In Q3, revenue surged 39% YoY to $24.4 billion, prompting management to raise its full-year sales guidance to $91-$92 billion, reflecting 40% growth from $65.18 billion in fiscal 2025.
Although Lilly trades at a premium to many of its healthcare peers at 40X forward earnings, its expanding obesity treatment franchise and robust drug pipeline provide compelling long-term growth catalysts that are less directly tied to economic cycles.
Image Source: Zacks Investment Research
Bottom Line
With technology volatility intensifying, AbbVie and Eli Lilly offer attractive ways to diversify into healthcare while maintaining exposure to long-term growth.
ABBV stands out for its dividend income and defensive characteristics, while LLY offers stronger growth potential, albeit with greater valuation risk.
Although they warrant some caution near 52-week highs, both stocks could be worthwhile portfolio additions for investors seeking greater stability outside the technology sector.
View the Zacks #1 Rank List
Image: Bigstock
2 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY
Key Takeaways
With technology stocks retreating amid concerns about lofty AI valuations and massive infrastructure spending, investors may want to consider defensive healthcare stocks that are showing impressive relative strength.
Notably, AbbVie (ABBV - Free Report) ) and Eli Lilly (LLY - Free Report) ) stocks have hit fresh 52-week highs after posting strong Q3 results last week, highlighting investors' appetite for established healthcare companies with resilient demand, strong earnings potential, and attractive long-term growth prospects.
Both stocks are up more than 25% in 2026 and have outperformed the broader market with returns of more than 100% in the last three years.
Image Source: Zacks Investment Research
AbbVie's Strong Growth & Rising Dividend
Hitting a fresh 52-week high of $302 a share on Thursday, AbbVie’s ascent has been supported by strong demand for its blockbuster immunology treatments Skyrizi and Rinvoq.
AbbVie's Q3 revenue climbed 10% year over year to $17.4 billion, with adjusted earnings more than doubling to $3.82 per share. Management also raised its full-year adjusted EPS outlook to a range of $13.95-$13.99, which would reflect more than 39% growth.
Adding to its defensive appeal, AbbVie recently announced a 5.2% dividend increase for 2027 to a quarterly payout of $1.82 per share, reinforcing its commitment to shareholder returns with a dividend yield comfortably above 2%.
Image Source: Zacks Investment Research
Eli Lilly's Explosive Obesity Drug Growth
Eli Lilly has emerged as one of the medical sector's strongest growth stories, with LLY shares also hitting a 52-week peak in today’s trading session of $1,453 a share.
Demand for blockbuster diabetes and obesity treatments Mounjaro and Zepbound continues to fuel exceptional growth. In Q3, revenue surged 39% YoY to $24.4 billion, prompting management to raise its full-year sales guidance to $91-$92 billion, reflecting 40% growth from $65.18 billion in fiscal 2025.
Although Lilly trades at a premium to many of its healthcare peers at 40X forward earnings, its expanding obesity treatment franchise and robust drug pipeline provide compelling long-term growth catalysts that are less directly tied to economic cycles.
Image Source: Zacks Investment Research
Bottom Line
With technology volatility intensifying, AbbVie and Eli Lilly offer attractive ways to diversify into healthcare while maintaining exposure to long-term growth.
ABBV stands out for its dividend income and defensive characteristics, while LLY offers stronger growth potential, albeit with greater valuation risk.
Although they warrant some caution near 52-week highs, both stocks could be worthwhile portfolio additions for investors seeking greater stability outside the technology sector.